News

Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 ...
Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...